ZIOPHARM Oncology Inc is a Delaware Corporation originally incorporated in Colorado in September 1998 under the name Net Escapes, Inc. and later changed its name to "EasyWeb, Inc." in February 1999. Following reincorporation in Delaware in May 2005 under the same name, the Company completed a reverse acquisition of privately held ZIOPHARM, Inc., a Delaware corporation on September 13, 2005. It is a biopharmaceutical company that seeks to acquire, develop and commercialize, on its own or with commercial partners, a portfolio of cancer therapies through synthetic biology. Palifosfamide, ZIO-201 is a small molecule palifosfamide, or isophosphoramide mustard, is a proprietary active metabolite of the pro-drug ifosfamide. Small-Cell Lung Cancer, or SCLC, is almost exclusively associated with smoking. Standard of care for SCLC, which is etoposide and platinum therapy, has changed little in decades. Darinaparsin, ZIO-101. Darinaparsin is an anti-mitochondrial compound covered by issued patents and pending patent applications in the United States and in foreign countries. Indibulin, ZIO-301. Indibulin is a novel, small molecule inhibitor of tubulin polymerization and is potentially safer than other tubulin inhibitors as no neurotoxicity has been observed in preclinical studies or in Phase 1 clinical trials. The Company is subject to government regulations.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.